{"id":440010,"date":"2021-02-19T11:14:16","date_gmt":"2021-02-19T16:14:16","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=440010"},"modified":"2021-02-19T11:14:16","modified_gmt":"2021-02-19T16:14:16","slug":"aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\/","title":{"rendered":"AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>, Feb. 19, 2021<\/span> \/PRNewswire\/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced the closing of its previously announced\u00a0underwritten public offering of 46,875,000 shares of its common stock at a price to the public of $1.60<\/span> per share. As previously announced, the Company has granted to the underwriter a 30-day option to purchase up to 7,031,250 additional shares of common stock at the public offering price, less underwriting discounts and commissions.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/AIkido
\n <\/a>\n <\/p>\n<\/p><\/div>\n

H.C. Wainwright & Co. acted as the sole book-running manager for the offering.<\/p>\n

The gross proceeds to the Company from the offering are $75 million<\/span>, before deducting underwriting discounts and commissions and other offering expenses. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.\u00a0<\/p>\n

The offering was conducted pursuant to the registration statement on Form S-3 (File No. 333-238172), as amended, previously filed with and subsequently declared effective by the Securities and Exchange Commission (“SEC”) on\u00a0June 18, 2020.\u00a0The offering was made only by means of a prospectus supplement and accompanying base prospectus. A final prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC and are available for free on the SEC’s website located at http:\/\/www.sec.gov<\/a>. and may also be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY<\/span> 10022, by telephone at (646) 975-6996, or by email to placements@hcwco.com<\/a>.<\/p>\n

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying base prospectus forming a part of the effective registration statement.<\/p>\n

\n About AIkido Pharma Inc.<\/b>\n <\/p>\n

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.\u00a0The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The\u00a0University of Texas<\/span> at Austin\u00a0and\u00a0Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.\u00a0The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.<\/p>\n

\n Forward-Looking Statements<\/b>\n <\/p>\n

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n

\n Contact:<\/b>\n <\/p>\n

Investor Relations:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n

Hayden IR
Brett Maas<\/span>, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com<\/a>
www.haydenir.com<\/a><\/p>\n

AIkido Pharma Inc.:\u00a0\u00a0\u00a0 <\/p>\n

Phone: 212-745-1373
Email: investorrelations@aikidopharma.com<\/a>
www.aikidopharma.com<\/a><\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock-301231770.html<\/a><\/p>\n

SOURCE AIkido Pharma Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK, Feb. 19, 2021 \/PRNewswire\/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced the closing of its previously announced\u00a0underwritten public offering of 46,875,000 shares of its common stock at a price to the public of $1.60 per share. As previously announced, the Company has granted to the underwriter a 30-day option to purchase up to 7,031,250 additional shares of common stock at the public offering price, less underwriting discounts and commissions. H.C. Wainwright & Co. acted as the sole book-running manager for the offering. The gross proceeds to the Company from the offering are $75 million, before deducting underwriting discounts and commissions and other offering expenses. The Company intends to use the net … <\/p>\n

Continue reading “AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-440010","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Feb. 19, 2021 \/PRNewswire\/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced the closing of its previously announced\u00a0underwritten public offering of 46,875,000 shares of its common stock at a price to the public of $1.60 per share. As previously announced, the Company has granted to the underwriter a 30-day option to purchase up to 7,031,250 additional shares of common stock at the public offering price, less underwriting discounts and commissions. H.C. Wainwright & Co. acted as the sole book-running manager for the offering. The gross proceeds to the Company from the offering are $75 million, before deducting underwriting discounts and commissions and other offering expenses. The Company intends to use the net … Continue reading "AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-19T16:14:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock\",\"datePublished\":\"2021-02-19T16:14:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\\\/\"},\"wordCount\":672,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1138079\\\/Aikida_Pharma_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\\\/\",\"name\":\"AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1138079\\\/Aikida_Pharma_Logo.jpg\",\"datePublished\":\"2021-02-19T16:14:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1138079\\\/Aikida_Pharma_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1138079\\\/Aikida_Pharma_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\/","og_locale":"en_US","og_type":"article","og_title":"AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock - Market Newsdesk","og_description":"PR Newswire NEW YORK, Feb. 19, 2021 \/PRNewswire\/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced the closing of its previously announced\u00a0underwritten public offering of 46,875,000 shares of its common stock at a price to the public of $1.60 per share. As previously announced, the Company has granted to the underwriter a 30-day option to purchase up to 7,031,250 additional shares of common stock at the public offering price, less underwriting discounts and commissions. H.C. Wainwright & Co. acted as the sole book-running manager for the offering. The gross proceeds to the Company from the offering are $75 million, before deducting underwriting discounts and commissions and other offering expenses. The Company intends to use the net … Continue reading \"AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-19T16:14:16+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock","datePublished":"2021-02-19T16:14:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\/"},"wordCount":672,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\/","name":"AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.jpg","datePublished":"2021-02-19T16:14:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-inc-announces-closing-of-75-million-bought-deal-offering-of-common-stock\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/440010","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=440010"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/440010\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=440010"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=440010"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=440010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}